Evolent Health Reports 46.9% Revenue Growth to $652.5 Million in Latest Quarter

Evolent Health, Inc. reported significant financial performance in its latest quarterly filing, with total revenue reaching $652.5 million for the three months ended June 30, 2026, marking a 46.9% increase from $444.3 million in the same period last year. For the first half of 2026, revenue totaled $1.15 billion, up 23.8% from $928.0 million in the prior year. The growth was primarily driven by a $216.8 million increase in Performance Suite contracts, despite a $12.7 million reduction in membership due to changes in health plan client enrollments and contract adjustments.

The company's operating loss for the second quarter was $9.6 million, compared to a loss of $1.2 million in the same quarter of 2025. For the six months ended June 30, 2026, the operating loss widened to $20.2 million from $2.8 million in the previous year. The increase in operating loss was attributed to a 66.2% rise in cost of revenue, which reached $571.7 million, largely due to higher claims costs associated with new Performance Suite contracts. Selling, general, and administrative expenses decreased by 8.5% to $68.8 million, reflecting lower personnel costs and professional fees.

Evolent Health's operational metrics showed a total of 6.7 million lives on its Performance Suite platform for the second quarter, with an average per-member-per-month (PMPM) fee of $24.05, up from $13.76 a year earlier. The company also reported a Medical Expense Ratio (MER) of 95.3% for its specialty care management services, indicating increased medical costs relative to revenue. The company’s total accounts receivable increased to $449.1 million, up from $309.9 million at the end of 2025, reflecting the timing of cash receipts and new contract go-lives.

Strategically, Evolent Health continues to focus on expanding its footprint in the healthcare market, particularly in specialty care management. The company has emphasized its commitment to integrating care for complex conditions and enhancing its technology platform to support healthcare providers. As of June 30, 2026, Evolent had $115.7 million in cash and cash equivalents, which it believes will be sufficient to meet its working capital needs for at least the next twelve months. The company remains cautious about future market conditions, particularly regarding inflationary pressures and potential impacts on membership and claims costs.